Ergoteles LLC cut its holdings in Magenta Therapeutics, Inc. (NASDAQ:MGTA – Get Rating) by 12.3% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 115,122 shares of the company’s stock after selling 16,155 shares during the period. Ergoteles LLC’s holdings in Magenta Therapeutics were worth $162,000 at the end of the most recent reporting period.
A number of other large investors have also recently made changes to their positions in MGTA. Wellington Management Group LLP purchased a new position in shares of Magenta Therapeutics during the 1st quarter worth about $3,786,000. Laurion Capital Management LP purchased a new position in shares of Magenta Therapeutics during the 2nd quarter worth about $699,000. Woodline Partners LP boosted its stake in shares of Magenta Therapeutics by 201.1% during the 1st quarter. Woodline Partners LP now owns 796,461 shares of the company’s stock worth $2,310,000 after purchasing an additional 531,984 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Magenta Therapeutics by 205.7% during the 2nd quarter. Renaissance Technologies LLC now owns 731,346 shares of the company’s stock worth $878,000 after purchasing an additional 492,081 shares during the period. Finally, Millennium Management LLC boosted its stake in shares of Magenta Therapeutics by 33.6% during the 2nd quarter. Millennium Management LLC now owns 1,875,395 shares of the company’s stock worth $2,250,000 after purchasing an additional 471,594 shares during the period. 76.68% of the stock is currently owned by institutional investors.
Insiders Place Their Bets
In other news, major shareholder Rock Ventures Iv L.P. Third sold 2,200,000 shares of Magenta Therapeutics stock in a transaction on Tuesday, February 7th. The stock was sold at an average price of $0.83, for a total value of $1,826,000.00. Following the transaction, the insider now directly owns 4,558,204 shares in the company, valued at approximately $3,783,309.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 11.56% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
Magenta Therapeutics Stock Up 2.8 %
MGTA opened at $0.81 on Wednesday. The stock’s fifty day moving average is $0.64 and its two-hundred day moving average is $1.08. The company has a market capitalization of $49.16 million, a P/E ratio of -0.63 and a beta of 2.10. Magenta Therapeutics, Inc. has a 52 week low of $0.32 and a 52 week high of $3.62.
About Magenta Therapeutics
Magenta Therapeutics, Inc is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. It offers patient preparation, stem cell collection, cell dose, and safe immune regeneration programs. Its platform include autologous and allogeneic transplant, and gene therapy.
- Get a free copy of the StockNews.com research report on Magenta Therapeutics (MGTA)
- Under-the-Radar Azul SA Takes Flight on Robust Travel Demand
- Market Gets “Powelled”: S&P 500 Confirms Resistance
- Rivian Plummets, But Is This 2023’s Greatest Buying Opportunity?
- Ulta Insiders Hold Tight: Sell-Siders Buy
- Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Want to see what other hedge funds are holding MGTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Magenta Therapeutics, Inc. (NASDAQ:MGTA – Get Rating).
Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.